RxDoctor Payments Data

Marcia Timmons

Nurse Practitioner · Locust Grove, GANPI 1336792886

Payments from drug & device makers

$3,610in general payments, 2019–2025

Across 187 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$664
  • Novo Nordisk$606
  • Lilly USA, LLC$532
  • GSK$171
  • Pfizer$164
  • AbbVie$147
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$3,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,610 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$20,836
Medicare patients
101
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$42,385
FarxigaDapagliflozin Propanediol29$29,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$27,697
TrulicityDulaglutide14$19,754
EliquisApixaban14$17,075
MounjaroTirzepatide11$13,861
Albuterol Sulfate HfaAlbuterol Sulfate55$1,343
Gabapentin49$740
Levothyroxine Sodium100$637
Atorvastatin Calcium109$627
Omeprazole35$613
Amitriptyline Hcl12$590
Ondansetron OdtOndansetron16$585
Torsemide12$500
Rosuvastatin Calcium45$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$606$42,38533 claims
Lilly USA, LLCTrulicity, Mounjaro$532$33,61625 claims
AstraZenecaFarxiga$664$29,98129 claims
GSKTrelegy Ellipta$171$27,69729 claims
PfizerEliquis$164$17,07514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Locust Grove

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →